Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk

References

• Bruckert E, Baccara-Dinet M, McCoy F,. et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-34
   PubMed Web of Science ®Google Scholar
• Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007;24:388-91
   PubMed Web of Science ®Google Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41
   PubMedGoogle Scholar
• Gordon T, Castelli WP, Hjortland MC,. et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
   PubMed Web of Science ®Google Scholar
• Drexel H, Aczel S, Marte T,. et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-7
   PubMed Web of Science ®Google Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13
   PubMed Web of Science ®Google Scholar
• Kitamura A, Iso H, Naito Y,. et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994;89:2533-9
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
   PubMed Web of Science ®Google Scholar
• Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88 (Suppl):14-18N
   Google Scholar
• Barter P, Gotto AM, LaRosa JC,. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA,. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627-37
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A,. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ,. et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Gille A, Bodor ET, Ahmed K,. et al. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008;48:79-106
   PubMed Web of Science ®Google Scholar
• Vogt A, Kassner U, Hostalek U,. et al. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag 2007;3:467-79
   PubMedGoogle Scholar
• Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98
   PubMed Web of Science ®Google Scholar
• Dunn RT, Ford MA, Rindone JP,. et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80
   PubMedGoogle Scholar
• Jungnickel PW, Maloley PA, Vander Tuin EL,. et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Kastelein JJ, Poldermans D,. et al. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007;23:1707-13
   PubMed Web of Science ®Google Scholar
• Vogt A, Kassner U, Hostalek U,. et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006; 22:417-25
   PubMed Web of Science ®Google Scholar
• Dunn RT, Ford MA, Rindone JP,. et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80
   PubMedGoogle Scholar